Details of the Drug Combination

General Information of Drug Combination (ID: DCCFSG1)

Drug Combination Name
ABT-199 CF102
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs ABT-199   DM2BLMT CF102   DMP56WJ
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 4.636
Bliss Independence Score: 5.714
Loewe Additivity Score: 7.642
LHighest Single Agent (HSA) Score: 11.543

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABT-199
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [2]
Indication(s) of CF102
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 2 [3]
Hepatitis C virus infection 1E51.1 Phase 1/2 [4]
CF102 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adenosine A3 receptor (ADORA3) TTJFY5U AA3R_HUMAN Agonist [4]
------------------------------------------------------------------------------------
CF102 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [5]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 Clinical pipeline report, company report or official report of Abbott Laboratories.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2011 Pipeline of Can-Fite BioPharm.
5 p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochem Pharmacol. 2002 Mar 1;63(5):871-80. doi: 10.1016/s0006-2952(02)00839-0.